SCHEMBL3693095

SCHEMBL3693095

CC1CCCN(S(=O)(=O)n2cc(C=O)nc2-c2ccccc2F)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.43
ALDH1A1 P00352 5/20 0.43
HTT P42858 3/20 0.43
MAPT P10636 2/20 0.43
HBB P68871 1/20 0.43
BAP1 Q92560 1/20 0.43
MEN1 O00255 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
POLB P06746 1/20 0.39
LRRK2 Q5S007 1/20 0.38
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RAC1 P63000 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TSHR P16473 3/20 0.35
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3694298 0.83 KMT2A (0.45) KMT2AALDH1A1HTTMAPTHBB
SCHEMBL3701032 0.71 PTGS2 (0.39) KMT2AALDH1A1HTTMEN1KDM4E
SCHEMBL4131785 0.70 KMT2A (0.40) KMT2AALDH1A1HTTMAPTHBB
SCHEMBL3697877 0.68 KMT2A (0.40) KMT2AALDH1A1MAPTMEN1NPC1
SCHEMBL3702782 0.68 PTGS2 (0.35) KMT2AHTTMAPTKDM4EPOLB
SCHEMBL3696262 0.66 PTGS2 (0.35) KDM4E
SCHEMBL3702135 0.66 PTGS2 (0.35) KMT2AALDH1A1MAPTKDM4EHPGD
SCHEMBL16301341 0.62 NPSR1 (0.68) KMT2AALDH1A1HTTMEN1KDM4E
SCHEMBL15014602 0.62 NPSR1 (0.68) KMT2AALDH1A1HTTMEN1KDM4E
SCHEMBL24226898 0.61 AKR1C3 (0.60) KMT2AALDH1A1HTTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 KMT2A 4776/4885ALDH1A1 1497/4885HTT 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.